Default company panoramic image

Eudendron Srl

Eudendron discovers novel Kinase Inhibitors for the treatment of cancer through innovative molecular designs and development strategies.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Colleretto Giacosa, Turin, Piedmont, Italy
  • Currency EUR
  • Founded July 2012
  • Employees 2
  • Website

Company Summary

Eudendron is a seed-stage Start-up company devoted to the discovery and development of a new generation of Kinase inhibitors, addressing crucial unmet medical needs in the area of oncology Personalized Medicine. Eudendron innovative molecular design aims to develop safer and effective drugs able to overcome drug resistance. Investments will be used to advance, up to proof-of-concept, candidate drugs that will be outlicensed to Pharma companies.


  • Default avatar
    Mauro Angiolini
    Chief Executive Officer

    Mauro Angiolini (43, PhD in Medicinal Chemistry) has 13 Years of experience in the field of Medicinal Chemistry drug discovery in Pharmaceutical Companies (Pharmacia, Pfizer) or Italian Biotech companies (Nerviano Medical Sciences). As Senior Medicinal Chemist he has been involved in many projects related to Oncology with different roles and responsibilities. In the last ten years he focused his research on Kinase Inhibitors drug discovery.

  • Default avatar
    Fabio Zuccotto
    Chief Scientific Officer

    Fabio Zuccotto (45, PhD in Computational Chemistry) has 13 years’ experience in Drug Discovery working both in Academic and Industrial settings. He spent most of his career in the UK. He returned to Italy working for Nerviano Medical Sciences where he was involved in the development of innovative molecular designs of Kinase inhibitors. He was also Team Leader of a multidisciplinary group of scientists focused on Fragment Based Drug Discovery.

Previous Investors

  • Default avatar
    Eudendron Srl never had Investors in the past.